NSE · SANGANI · Healthcare
Sangani Hospitals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹23 Cr with net profit ₹3 Cr — a 11.38% net margin, versus 15.63% the period before.
Shareholding
As of 2026-06-30
- Promoter74.09%
- Public25.91%
444 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.08× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 79 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.07 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.34 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,517 Cr | 135.03 | 8.94 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.47 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
| Sangani Hospitals Limited(this company) | — | 24.71 | 1.54 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashSangani Hospitals Limited operates in the Healthcare sector. The company has a market capitalization of Rs 62 Cr. Its debt-to-equity ratio is 0, and the price-to-earnings ratio stands at 25.8. The book value per share is Rs 27.94, with an EPS of Rs 1.74. The company's ROCE is 9.93%. Over the last year, the share price has ranged from a 52-week low of Rs 37 to a 52-week high of Rs 77.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Revenue grew by 29.09% in the latest annual period.
- +Promoter holding is high at 74.0872% as of March 31, 2026.
Negatives
- −Earnings per share decreased from Rs 2.17 in Mar 2024 to Rs 1.88 in Mar 2025.
- −Return on equity (ROE) and profit margin figures are not available for assessment.
- −Promoter holding has decreased from 100% in May 2023 to 74.0872% in March 2026.
- −No quarterly results have been disclosed.
Financial Performance
Sangani Hospitals Limited reported a revenue of Rs 22.7918 Cr in March 2025, which represents a 29.09% revenue growth. Net profit for the same period was Rs 2.5927 Cr. Earnings per share decreased from Rs 2.17 in March 2024 to Rs 1.88 in March 2025.
Profitability & Returns
The company's return on capital employed (ROCE) is 9.93%. The price-to-earnings (P/E) ratio is 25.8, based on an EPS of Rs 1.74. No data for return on equity (ROE) or profit margin has been provided.
Balance Sheet
Sangani Hospitals Limited has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 27.94. Further details on assets and liabilities are not available in the provided data.
Ownership & Pledges
Public shareholding stands at 25.9128%. There has been a decrease in promoter holding from 74.0872% in March 2026 compared to 100% in May 2023. No promoter shares are pledged.
Regulatory & Surveillance
The company is not currently under any form of surveillance. There were no FII or DII holdings as of March 31, 2026. The number of shareholders as of March 31, 2026, is 440.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.